Alto Neuroscience (NYSE:ANRO) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Alto Neuroscience (NYSE:ANRO) issued its quarterly earnings results on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08, FiscalAI reports.

Alto Neuroscience Stock Up 1.2%

Shares of ANRO stock traded up $0.34 during trading hours on Wednesday, reaching $29.12. The company had a trading volume of 277,788 shares, compared to its average volume of 365,603. The company has a market capitalization of $1.02 billion, a P/E ratio of -12.03 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. Alto Neuroscience has a twelve month low of $3.02 and a twelve month high of $29.70. The stock’s fifty day simple moving average is $25.24 and its 200 day simple moving average is $22.48.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Bank of America initiated coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target for the company. Wedbush upped their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors have recently added to or reduced their stakes in ANRO. XTX Topco Ltd boosted its position in shares of Alto Neuroscience by 32.2% during the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience during the fourth quarter valued at about $198,000. Armistice Capital LLC grew its position in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after buying an additional 12,000 shares in the last quarter. Ieq Capital LLC increased its stake in Alto Neuroscience by 19.6% during the 4th quarter. Ieq Capital LLC now owns 75,294 shares of the company’s stock valued at $1,340,000 after buying an additional 12,315 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience during the fourth quarter valued at about $221,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.